Table 1.
Baseline Patient and Treatment Characteristics
| No XRT, n (%) | XRT, n (%) | OR | 95% CI | P Value | |
|---|---|---|---|---|---|
| Total patients | 2169 | 1882 | |||
| Gender | |||||
| Male | 1352 (62.3) | 1150 (61.1) | 1 | Reference | |
| Female | 817 (37.7) | 732 (38.9) | 1.05 | 0.93–1.20 | .423 |
| Age, y | |||||
| ≤ 65 | 1591 (73.4) | 1527 (81.1) | 1 | Reference | |
| > 65 | 578 (26.6) | 355 (18.9) | 0.64 | 0.55–0.7 | < .0001 |
| Insurance | |||||
| Insured | 2067 (95.3) | 1780 (94.6) | 1 | Reference | |
| Uninsured | 102 (4.7) | 102 (5.4) | 1.16 | 0.88–1.54 | .298 |
| Income, $ | |||||
| < 48,000 | 877 (40.4) | 733 (38.9) | 1 | Reference | |
| ≥ 48,000 | 1292 (59.6) | 1149 (61.1) | 1.06 | 0.94–1.21 | .335 |
| Facility | |||||
| Community | 1377 (63.5) | 1196 (63.6) | 1 | Reference | |
| Academic | 792 (36.5) | 686 (36.4) | 1.00 | 0.88–1.13 | .966 |
| Population | |||||
| Metro/urban | 2049 (94.5) | 1760 (93.5) | 1 | Reference | |
| Rural | 120 (5.5) | 122 (6.5) | 1.18 | 0.91–1.54 | .204 |
| Comorbidity score | |||||
| 0 | 1781 (82.1) | 1592 (84.6) | 1 | Reference | |
| ≥ 1 | 388 (17.9) | 290 (15.4) | 0.84 | 0.71–0.99 | .035 |
| Clinical T stage | |||||
| T1/T2 | 233 (10.7) | 155 (8.2) | 1 | Reference | |
| T3/T4 | 1009 (46.5) | 1309 (69.6) | 1.95 | 1.57–2.43 | < .0001 |
| Unknown | 927 (42.7) | 418 (22.2) | 0.68 | 0.54–0.86 | .001 |
| Clinical N stage | |||||
| N0 | 659 (30.4) | 498 (26.5) | 1 | Reference | |
| N1 | 593 (27.3) | 782 (41.5) | 1.75 | 1.49–2.04 | < .0001 |
| N2 | 336 (15.5) | 294 (15.6) | 1.16 | 0.95–1.41 | .141 |
| Unknown | 581 (26.8) | 308 (16.4) | 0.70 | 0.59–0.84 | .0001 |
| Grade | |||||
| 1–2 | 1777 (81.9) | 1581 (84.0) | 1.0 | Reference | |
| 3 | 392 (18.1) | 301 (16.0) | 0.86 | 0.73–1.02 | .080 |
| Metastatic burden | |||||
| 1 organ involved | 858 (39.6) | 783 (41.6) | 1 | Reference | |
| Multiple organs involved | 1311 (60.4) | 1099 (58.4) | 0.92 | 0.81–1.04 | .186 |
Abbreviations: CI = confidence interval; OR = odds ratio; XRT = pelvic radiotherapy.